Syndrome News and Research

RSS

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta) reduced the rate of cardiovascular (CV) events (CV death, myocardial infarction or stroke) from 11.7% to 9.8% compared clopidogrel (Plavix®) XX% (p<0.001, RRR = 16%), without an increase in major bleeding.

2 Sep 2009

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

LTS LOHMANN Therapie-Systeme AG, the leading developer and manufacturer of transdermal, topical and oral systems with facilities in Andernach, Germany and West Caldwell, New Jersey, celebrates its 25th anniversary.

1 Sep 2009

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).

1 Sep 2009

MultiGEN Diagnostics launches new technology for clinical testing in molecular diagnostics

San Diego-based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA sequencing technology (MultiGEN) for a wide range of clinical testing in molecular diagnostics.

1 Sep 2009

VAERS calls for reporting of GBS cases following 2009 H1N1 flu vaccination

The Centers for Disease Control and Prevention (CDC) and the American Academy of Neurology (AAN) are requesting neurologists to report any possible new cases of Guillain-Barr- syndrome (GBS) following 2009 H1N1 flu vaccination using the CDC and U. S. Food and Drug Administration Vaccine Adverse Event Reporting System (VAERS).

1 Sep 2009

New vaccine technology may prove beneficial for treating IGF-1 responsive disorders

Braasch Biotech LLC announces its lead vaccine for Obesity, Growth Hormone Deficiencies may have beneficial use for numerous IGF-1 responsive disorders such as diabetes, heart disease and Rett Syndrome based on initial preclinical testing in a mouse model.

1 Sep 2009

Study provides insights into genes that help maintain youthfulness of the skin

In the new print issue of Nature Genetics, scientists in Singapore and Germany report that mutations in the PYCR1 gene cause the rare genetic condition that results in premature skin aging and that is known as "wrinkly skin syndrome."

1 Sep 2009

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.

31 Aug 2009

Intermediate dosages of otamixaban reduce acute coronary complications

30 Aug 2009

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009

Film released on people with Asperger Syndrome

Torontonian Gail Hawkins - founder of an Asperger Syndrome employment consultancy - is the author of a practical guide for the Asperger population that figures prominently in director Max Mayer's new feature film "Adam", the Alfred P. Sloan prize winner at the 2009 Sundance Film Festival.

28 Aug 2009

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

Fatostatin lowers the activity of genes associated with cholesterol synthesis

A small molecule earlier found to have both anti-fat and anti-cancer abilities works as a literal turnoff for fat-making genes, according to a new report in the August 28th issue of the journal Chemistry and Biology, a Cell Press journal.

27 Aug 2009

Rutgers University Professor receives $3.5 million MERIT Award from NIH

Rutgers University Professor Dipak Sarkar has received a $3.5 million MERIT Award from the National Institutes of Health (NIH) to continue researching the damaging effects of alcohol on the nervous systems of the unborn.

27 Aug 2009

Department of Veterans Affairs cancels contract with UTSWMC for Gulf War research

Citing persistent noncompliance and numerous performance deficiencies, the Department of Veterans Affairs (VA) will not exercise the third year of a five-year, $75 million contract with the University of Texas Southwestern Medical Center (UTSWMC) to perform research into Gulf War Veterans' Illnesses (GWVI).

27 Aug 2009

UT Southwestern regrets VA's unilateral decision to not renew the Gulf War research contract

We regret the VA's unilateral decision to not renew the contract supporting vital research focused on veterans suffering from Gulf War syndrome being carried out by UT Southwestern investigators and their collaborators elsewhere.

27 Aug 2009

Fluidigm manufactures more than 250 million microscopic NanoFlex valves at its Singapore biochip factory

Fluidigm today announced that its Singapore biochip factory has manufactured and shipped more than 250 million microscopic NanoFlex™ valves. The 250 million valves built into Fluidigm’s integrated fluidic circuits (IFCs) would be equivalent to the number of valves required for all the conventional plumbing – both residential and commercial – in a metropolitan region the size of the San Francisco Bay Area.

27 Aug 2009

Kudzu vine root extracts may be developed as a dietary supplement for people with metabolic syndrome

Kudzu, the nuisance vine that has overgrown almost 10 million acres in the southeastern United States, may sprout into a dietary supplement.

27 Aug 2009

Syndrome News and Research

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

MultiGEN Diagnostics launches new technology for clinical testing in molecular diagnostics

VAERS calls for reporting of GBS cases following 2009 H1N1 flu vaccination

New vaccine technology may prove beneficial for treating IGF-1 responsive disorders

Study provides insights into genes that help maintain youthfulness of the skin

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Intermediate dosages of otamixaban reduce acute coronary complications

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Film released on people with Asperger Syndrome

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Fatostatin lowers the activity of genes associated with cholesterol synthesis

Rutgers University Professor receives $3.5 million MERIT Award from NIH

Department of Veterans Affairs cancels contract with UTSWMC for Gulf War research

UT Southwestern regrets VA's unilateral decision to not renew the Gulf War research contract

Fluidigm manufactures more than 250 million microscopic NanoFlex valves at its Singapore biochip factory

Kudzu vine root extracts may be developed as a dietary supplement for people with metabolic syndrome

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News